GRAIL (Nasdaq: GRAL) on April 7 announced it will integrate its Galleri multi-cancer early detection test into Epic's electronic health record platform, enabling providers at approximately 450 health systems to order the test, receive results, and manage patient follow-up within their native EHR workflow, the company said. Implementation planning began in the first quarter of 2026.
The Epic Aura integration allows clinicians to order Galleri directly at the point of care and view results inside the same patient portal, eliminating manual ordering steps. Epic is one of the most widely used EHR platforms in the United States. GRAIL cited a core clinical rationale: only five cancers in the U.S. currently have recommended screening, yet more than 70% of cancer deaths are caused by cancers without a recommended screening test, according to the company.
The announcement comes two days before GRAIL shares fell on news that Galleri missed its primary endpoint in the NHS-Galleri trial, as BaseCall reported. The Epic integration was announced the same day as the trial result. Some UK clinicians continue offering early access to the test pending the full data readout, but the endpoint miss complicates the regulatory and reimbursement case in both markets.
The competitive environment is intensifying. BaseCall reported this week that Abbott is in advanced talks to acquire Exact Sciences for $21 billion to $23 billion, a deal that would give the medtech conglomerate control of the Cologuard colorectal screening franchise. GRAIL's move to embed Galleri into clinical workflows via Epic could create switching costs once a test is integrated into EHR ordering, but only if ordering volume follows. The company did not disclose projected test volume increases or revenue impact from the Epic deal.
GRAIL President Josh Ofman, MD, characterized administrative burden as a barrier to adoption. Bloomberg reported that Jeff Bezos is backing GRAIL as the company plans a broader commercial push for the multi-cancer test.